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Abstract
Background: Ovarian cancer is the fifth leading cause of cancer deaths among women. Early stage disease often remains
undetected due the lack of symptoms and reliable biomarkers. The identification of early genetic changes could provide
insights into novel signaling pathways that may be exploited for early detection and treatment.
Methodology/Principal Findings: Mouse ovarian surface epithelial (MOSE) cells were used to identify stage-dependent
changes in gene expression levels and signal transduction pathways by mouse whole genome microarray analyses and
gene ontology. These cells have undergone spontaneous transformation in cell culture and transitioned from non-
tumorigenic to intermediate and aggressive, malignant phenotypes. Significantly changed genes were overrepresented in a
number of pathways, most notably the cytoskeleton functional category. Concurrent with gene expression changes, the
cytoskeletal architecture became progressively disorganized, resulting in aberrant expression or subcellular distribution of
key cytoskeletal regulatory proteins (focal adhesion kinase, a-actinin, and vinculin). The cytoskeletal disorganization was
accompanied by altered patterns of serine and tyrosine phosphorylation as well as changed expression and subcellular
localization of integral signaling intermediates APC and PKCbII.
Conclusions/Significance: Our studies have identified genes that are aberrantly expressed during MOSE cell neoplastic
progression. We show that early stage dysregulation of actin microfilaments is followed by progressive disorganization of
microtubules and intermediate filaments at later stages. These stage-specific, step-wise changes provide further insights
into the time and spatial sequence of events that lead to the fully transformed state since these changes are also observed
in aggressive human ovarian cancer cell lines independent of their histological type. Moreover, our studies support a link
between aberrant cytoskeleton organization and regulation of important downstream signaling events that may be
involved in cancer progression. Thus, our MOSE-derived cell model represents a unique model for in depth mechanistic
studies of ovarian cancer progression.
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Introduction
Ovarian cancer accounts for only 3% of diagnosed cancers, but
is the fifth leading cause of cancer deaths among woman, with five-
year survival rates of only 45% [1]. The average age of diagnosis is
63 years of age, and most patients (62%) present with metastatic
disease at time of diagnosis [1]. Ovarian cancer is a heterogeneous
disease with various histo- or clinicopathological subtypes that
develop and present differently. The conventional view is that
approximately 90% of ovarian cancers are derived from the single-
cell layer of surface epithelium that surrounds the ovary [2]. As the
ovarian epithelium transforms into a malignant phenotype, it
differentiates into several subtypes that have been categorized into
serous, mucinous, endometrioid and clear cell carcinoma, based
on their morphology rather than their genotype [3]. However, the
origin of individual subtypes may vary and a higher contribution
from fallopian tubes and the endometrium to more aggressive
cancers is currently in discussion [4]. The origin of both ovarian
and fallopian epithelial is the same, namely the coelomic
epithelium [2] which may contribute to the controversy.
Epithelial ovarian cancers show a high degree of genetic
heterogeneity as a result of mutations, silencing, and deletions.
Since changes in gene expression, either through mutation,
epigenetic regulation, or differential splicing events, influence
tumor development, progression, drug responsiveness and
ultimately the survival of the patient, the identification of the
tumor subtype and its genetic fingerprint is essential. Recently,
a new classification of epithelial ovarian tumors into type I and
type II cancers has been proposed: type 1 are benign to
borderline tumors with relatively stable genotypes while type II
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17676includes aggressive and high grade tumors that are genetically
instable and exhibit substantial genetic changes [5]. Most
epithelial cancers follow a progression scheme in which
initiated cells progress to adenomas to adenocarcinomas and
metastasis, accumulating genetic alterations in a stepwise
manner during progression [6]. This sequence has also been
described for low-grade ovarian carcinomas; it is, however,
debated if all ovarian cancers follow this cancer development
since precursor lesions for the most aggressive ovarian tumors
(type II) have not been conclusively identified [5]. Recently,
Lee et al. have proposed that the fimbria of the fallopian tube
may be the origin for ‘‘Type II’’ serous carcinomas cells [7].
They propose that type II tumors arise from ‘‘p53 signature’’
precursor lesions originating from amplification of secretory
epithelial cells. Subsequent mutations then facilitate progression
to serous tubal intraepithelial carcinoma and ultimately to
serous carcinoma.
Currently, gene expression patterns have only been used
successfully to distinguish between mucinous and clear cell from
serous carcinomas [8] or between low-grade, low malignant
potential and high-grade, metastatic tumors [9,10,11]. Reliable
molecular or clinical markers to identify changes in the early stages
of progression have not been established yet, and since the early
stages of the disease are relatively asymptomatic the diagnosis
often only occurs at late stages. Therefore, the characterization of
gene expression profiles of early stage precursor lesions of ovarian
cancer could provide new insights and identify novel targets for
preventive and treatment efforts.
We have previously developed and characterized a cell model
of epithelial ovarian cancer progression to study the sequence of
events that lead to epithelial ovarian cancer [12]. The syngeneic
mouse ovarian surface epithelial (MOSE) cells, derived from the
C57BL6 mice, have undergone spontaneous transformation in
cell culture. The heterogeneous MOSE cells undergo distinct
phenotypical changes as they are continuously passaged in
culture, with early passages representing a premalignant, non-
tumorigenic phenotype, intermediate passages representing a
transitional phenotype, and later passages progressing to a highly
aggressive malignant phenotype when administered to immuno-
competent mice. Transitional states of progression were distin-
guishable by alterations in growth rates, cell size, loss of contact
inhibition of growth, and the capacity to grow as spheroids under
non-adherent conditions. Importantly, both the MOSE-I (inter-
mediate passage) and MOSE-L (late passage) cells have also
acquired the capacity to form tumors when injected into the
peritoneal cavity of syngeneic immunocompetent mice, albeit the
former was less invasive [12].
In the present study, we identified significant changes in gene
expression patterns as non-transformed MOSE-derived cells
transition to more aggressive phenotypes and used gene ontology
tools to determine their functional categories. The transitional
states of this model allowed us to identify stage-dependent genes,
gene products and signal transduction pathways involved in
ovarian tumor progression. Here we highlight progressive
changes that lead to a highly dysregulated cytoskeleton. Many
of these changes were confirmed in archived human ovarian
cancer microarray data sets. Importantly, we demonstrate that
cytoskeleton disorganization can have profound effects on the
subcellular localization of important signaling intermediates,
which ultimately may lead to modulated signaling pathways
contributing to ovarian cancer development. These genes, their
gene products and the associated signaling pathways may
represent novel targets for early intervention of neoplastic
progression.
Results
Differentially regulated genes in mouse ovarian cancer
progression
To identify gene expression changes during the progression of
epithelial ovarian cancer and determine potential stage-specific
patterns, we used whole genome microarray analysis to compare
gene expression levels in cells representing benign (MOSE-E),
intermediate (MOSE-I), and malignant (MOSE-L) stages of mouse
ovarian cancer. Three biological replicates were used to take into
account variations within the heterogeneous cultures. Of the
45,102 probe sets on the microarray (representing 18,136
annotated genes), 960 probe sets were found to be significantly
up-regulated (701 annotated genes) and 1006 were significantly
down-regulated (711 annotated genes) greater that 2 fold (p#0.05)
between MOSE-E and MOSE-L cells. Of these 1966 changing
probe sets, 58.9% exhibited no significant change in expression
levels during the progression between MOSE-E and MOSE-I,
indicating the majority of changes in gene expression are
associated with later events in the malignant progression in our
model, with 608 increasing and 549 decreasing as cells transition
from MOSE-I to MOSE-L. In contrast, 33.3% of the affected
genes showed a progressive increase (272 probe sets) or decrease
(382 probe sets) in expression as cells transition from MOSE-E to
MOSE-I to MOSE-L cells (Figure 1). A small number of affected
Figure 1. Gene expression changes during progression of
MOSE cells. Of 45,102 probe sets analyzed, 970 were significantly
(p#0.05) up-regulated (A) and 1006 were down-regulated (B) greater
than two fold. Arrows indicate pattern of expression changes with
number of probe sets indicated next to the arrow. Probe sets indicated
as other did not follow the described patterns.
doi:10.1371/journal.pone.0017676.g001
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were within 0.4 fold of MOSE-L/MOSE-E ratios, indicating that
these gene expression changes may be associated with very early
events in malignant progression of our cells. Together these data
indicate that most of the changes in gene expression levels either
occur continually, in a stepwise fashion, throughout the progres-
sion of our model or take place in later stages while only a limited
subset change during early stages. The complete data set can be
found in the GEO data base (GSE24789).
Over-represented gene ontology categories in ovarian
cancer progression
To detect pathways that may contribute to the promotion and
progression of ovarian cancer, the Gene Trail program was used
to identify the functional categories of genes that demonstrate
statistically significant changes in their expression levels between
MOSE-E and MOSE-L cells. Gene Trail is an advanced gene set
enrichment analysis tool that determines over-represented gene
ontology categories in data sets [13]. The over-represented cellular
component, biological process, and molecular function gene
ontology categories found in the MOSE-L versus MOSE-E
differentially expressed gene sets are listed in Table 1 (p,0.01).
Over-representation of genes in the cell cycle and cell proliferation
categories was anticipated due to the previously reported increased
growth rate of the MOSE-L cells [12] and the involvement of the
uncontrolled cell proliferation in cancer [14]. Interestingly, the
cytoskeleton and Metal Ion/Cation binding categories represented
a significant number of the differentially expressed genes, with a
substantial overlap of genes categorized in both of these ontology
categories. However, in contrast to the broad range of functions of
the genes in the Metal Ion/Cation binding category, genes
compiled in the cytoskeleton gene ontology category were
functionally very specific. Since it is thought that changes in the
expression levels of cytoskeletal proteins and their regulators are
associated with progression and metastasis [15,16,17], the changes
in genes involved in the structure and regulation of the
cytoskeleton during progression of our MOSE model were the
subject of further investigation.
Disorganization of the cellular cytoskeleton during
malignant progression
Actin Cytoskeleton. Of the 141 genes categorized within the
cytoskeleton gene ontology category, 90 have gene products that
are subunits of actin filaments (Table 2) or are involved in the
organization and regulation of the actin cytoskeleton (Table 3; full
list in supplemental Table S1). For most of these genes, expression
levels gradually changed in a stepwise manner as cells transitioned
from MOSE-E to MOSE-I to MOSE-L, indicating that these
changes are continuously occurring throughout progression. Only
three genes, c-actin 1, formin 1, and drebrin 1, demonstrated
MOSE-I/MOSE-E ratios that were within less than 0.4 fold of
MOSE-L/MOSE-E ratios, suggesting these are early changes in
malignant progression (Table 2 and 3). Seven genes, including
integrin-av, -b1, and -b2, showed expression levels that changed
by the greatest magnitude in MOSE-I cells, two of which were
confirmed by qRT-PCR (Table 2 and Table 3). A large number of
these genes are dysregulated in cancer or involved in metastasis
including all of the 15 genes that were confirmed by qRT-PCR
(Table 2 and 3).
The gene products of a subset of genes confirmed by qRT-PCR
were also analyzed by western blot as well as immunofluorescence
microscopy to determine potential differences in their subcellular
localization. The microarray results indicated a progressive
decrease of a-actin and c-actin mRNA, which was confirmed by
qRT-PCR (Table 2), however, no changes of b-actin were
observed. This corresponded to a decrease in total actin protein
levels during progression (Figure 2A). Furthermore, examination
of F-actin architecture by immunofluorescence microscopy
revealed distinct differences of the actin subcellular organization.
MOSE-E cells exhibited long, well-defined cable-like stress fibers
after staining with Alexa Fluor
488 conjugated phalloidin, whereas
the malignant MOSE-L cells displayed less distinct F-actin
structures and organization. (Figure 3A, 1
st column). In MOSE-
L cells, actin structures ranged from small thin stress fibers to
prominent ‘‘ruffled’’ zones with very short actin filaments,
reminiscent of podosomes (Figure 3A and 3B, confocal image 2
inset). Of note, the MOSE-I exhibited F-actin disorganization
similar to that of MOSE-L cells (Figure 3A). To specifically
compare cellular F-actin content between MOSE cell lines, a
procedure based on fluorescently conjugated phalloidin was
employed. As shown in Figure 4, total cellular F-actin was
decreased by 78% (p,0.01) in MOSE-L cells compared to
MOSE-E cells, confirming qRT-PCR and Western results.
Confocal microscopy revealed large difference in the thickness of
the cells; MOSE-E cells had an average thickness of 2 mm,
indicating these cells are rather flat when grown on plastic, while
MOSE-L cells exhibited an average thickness of 4.4 mm across
cytoplasmic regions. The confocal images shown in Figure 3B
Table 1. Over Represented Gene Ontology Categories by
Differentially Expressed Genes in MOSE Cell Stages Late vs.
Early.
Cellular Component
Number of Genes
Regulated
Cytoskeleton 141
Actin Cytoskeleton 90
Microtubule Cytoskeleton 44
Intermediate Filament cytoskeleton 7
Metal Ion/Cation Binding 254
Cell Cycle 106
Lipid/Steroid Metabolism 79
Intracellular Transport 71
Cell Proliferation 68
Golgi Apparatus 68
Chromosome 42
Extracellular Matrix 38
Membrane Organization 35
Tyrosine Kinase Receptor Signaling Pathway 30
Lysosome 25
Protein Translation 16
Tyrosine Phosphatase 16
Exonuclease Activity 12
Nuclear Pore 11
Insulin-like Growth Factor Binding 7
Non-G-Protein Coupled 7 TM Receptor Activity 5
Gene Trail program was used to analyze genes that are expressed above
background and demonstrate statistically significant changes in gene
expression between MOSE-E and MOSE-L cells. Cellular component, biological
process, and molecular function gene ontology categories significantly over-
represented (p,0.01) are listed.
doi:10.1371/journal.pone.0017676.t001
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starting at the base of the cell where actin fibers are found
abundantly at attachment sites. Since the average MOSE-L cell is
4.4 mm thick, the second image captures approximately the middle
third of the cell, not the membrane, suggesting the non-fibrous
structures in MOSE-L cells are not the result of membrane ruffling.
However, they are within the cell cytoplasm and are reminiscent of
structures characterizedin invasivebreastcancer cells as podosomes
[18]. In contrast, MOSE-E (Figure 3B) cells showed stress fibers
throughout the cells with no short actin filaments.
Microtubules. Gene products that compose or regulate the
microtubule network comprised the second largest set of genes (44
of 141) affected during neoplastic transformation of MOSE cells
(Table 4; full list in supplemental Table S2). All but six genes are
only up- or down-regulated in the MOSE-L cells. Five genes
(Tubb2b, Cenpe, Mtap6, Ndn, and Vav2) had expression levels
that gradually change from MOSE-E to MOSE-I to MOSE-L,
indicating that these changes are continuously occurring
throughout progression. Only one gene, Ninl, demonstrated
MOSE-I/MOSE-E ratios that where within less than 0.4 fold of
MOSE-L/MOSE-E ratios, suggesting that this is an early event in
malignant progression (Table 4). Interestingly, of the 44
differentially expressed microtubule and microtubule-associated
genes, 12 genes encode for proteins involved in chromosome
congression (Kif18a, Kif22, Kif4), segregation (Aspm Cenpe,
Ckap2, Incenp, Jub, Kif20a, Kif23, Lats2, Prc1), and/or
cytokinesis (Incenp, Kif20a, Kif23, Prc1) (Table 4) [19]. All 12
genes exhibited decreased expression with five of the 12 genes
coding for kinesins which are molecular motors that use the energy
of ATP hydrolysis to move along the surface of microtubule
filaments or destabilize them [19,20].
A significant decrease in the levels of a-tubulin isoform 4a and
multiple isoforms of b-tubulin were also noted in the microarray
data. Confirmation by qRT-PCR of individual isoforms proved
difficult because of high levels of homology, but the decrease of
tubulin b3 mRNA in MOSE-L cells was confirmed. However, no
significant changes of b-tubulin protein levels between MOSE-E
and MOSE-L cells were detected (Figure 2B). In contrast, a-
tubulin protein levels were decreased by 34% in MOSE-L cells
and 67% in MOSE-I cells when compared to MOSE-E levels. No
significant changes in c-tubulin mRNA (data not shown) or
protein levels (Figure 2B) were observed and immunostaining
revealed no readily discernible differences in protein localization
between MOSE-E and MOSE-L cells (data not shown).
Importantly, there were notable differences between MOSE-E
and MOSE-L cells when the subcellular organization of
microtubule proteins, a- and b-tubulin, were examined by
immunofluorescence (Figure 3A). In MOSE-E cells, both a- and
b-tubulin appear as long defined filaments radiating from what is
likely to be the perinuclear localized centriole (Figure 3A, 2
nd and
3
rd columns top panel), reported to be a normal organization of
tubulin in epithelial cells. In contrast, in MOSE-L cells tubulin
filaments were less defined, exhibiting random disorganized
branching and the origin of tubulin polymerization was not
readily apparent in many cells (Figure 3A, 2
nd and 3
rd columns,
bottom panel). MOSE-I cells appear to have an intermediate
Table 2. Differentially expressed actin and focal adhesion associated genes in MOSE cell stages.
Gene symbol Gene Name Accession Number I/E p-val L/E p-val
Actin
Acta1 alpha actin 1 NM_009606 22.2 0.0547 22.6 0.0487
Acta2 alpha actin 2 NM_007392 22.8 0.0698 219.3 0.0139
Actg1* gamma actin 1 NM_009609 22.1 0.0331 22.1 0.0331
Actg2 gamma actin 2 NM_009610 28.6 0.0742 212.6 0.0552
Focal Adhesion
Actn1 actinin, alpha 1 NM_134156 23.8 0.0454 25.3 0.0347
Fblim1 filamin binding LIM protein 1 NM_133754 21.6 0.1103 22.5 0.0282
Itga7 integrin alpha 7 NM_008398 25.3 0.0179 27.1 0.0116
Itgav Integrin alpha V NM_008402 23.7 0.0079 21.5 0.2389
Itgb1 Integrin beta 1 NM_010578 22.1 0.0441 1.1 0.7088
Itgb2 integrin beta 2 NM_008404 7.2 0.0059 4.1 0.0365
Itgb5 integrin beta 5 NM_010580 1.7 0.0347 2.7 0.0313
Lasp1 LIM and SH3 protein 1 NM_010688 21.2 0.2772 22.7 0.0015
Nck2 non-catalytic region tyrosine kinase adaptor protein 2 NM_010879 1.6 0.0027 2.7 0.0097
Parva parvin, alpha NM_020606 22.0 0.0646 23.3 0.0314
Pxn Paxillin NM_133915 1.4 0.0765 2.2 0.0094
Tgfb1i1 TGF beta 1 induced transcript 1 NM_009365 23.7 0.0668 249.0 0.0251
Tns1 tensin 1 NM_027884 22.3 0.0520 25.1 0.0162
Vcl Vinculin NM_009502 22.4 0.0658 23.8 0.0355
Zyx Zyxin NM_011777 23.8 0.0383 24.5 0.0317
List of genes differentially regulated (fold differences $2, p,0.05) which are structural or regulatory proteins of the actin cytoskeleton. Genes in italics were analyzed by
qRT-PCR, in bold were validated to change significantly between MOSE-E and MOSE-L cells, and those not in bold were validated to change significantly (p,0.05)
between MOSE-E and MOSE-I cells.
*denotes genes that are already changed in MOSE-I and maintain these expression levels in MOSE-L.
doi:10.1371/journal.pone.0017676.t002
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along with shorter, less defined filaments than in MOSE-E cells
(Figure 3A, 2
nd and 3
rd column, middle panels).
Intermediate Filaments. The final subset of affected
cytoskeleton associated genes (7/141) have gene products that
make up and regulate the intermediate filament (IF) network. The
Table 3. Differentially expressed actin binding regulating genes in MOSE cell stages.
Gene symbol Gene Name Accession Number I/E p-val L/E p-val
Actr3 ARP3 actin-related protein 3 homolog (yeast) NM_023735 21.4 0.0095 22.0 0.0102
Akap12 A kinase (PRKA) anchor protein (gravin) 12 NM_031185 29.9 0.0151 211.8 0.0141
Anln anillin, actin binding protein NM_028390 21.5 0.0408 22.5 0.0144
Arhgap24 Rho GTPase activating protein 24 NM_029270 28.5 0.0096 239.4 0.0059
Arhgap6 Rho GTPase activating protein 6 NM_009707 2.5 0.1591 12.8 0.0033
Arpc5l actin related protein 2/3 complex, subunit 5-like NM_028809 1.7 0.0110 2.5 0.0150
Cap1
+ CAP, adenylate cyclase-associated protein 1 NM_007598 22.5 0.0014 22.1 0.0260
Cdc42ep2 CDC42 effector protein (Rho GTPase binding) 2 NM_026772 1.5 0.2568 23.1 0.0029
Cdc42ep3 CDC42 effector protein (Rho GTPase binding) 3 NM_026514 21.8 0.0276 23.1 0.0063
Cdc42ep5 CDC42 effector protein (Rho GTPase binding) 5 NM_021454 1.1 0.7844 23.6 0.0013
Dbn1
* drebrin 1 NM_019813 22.1 0.0034 22.1 0.0021
Diap3 diaphanous homolog 3 (Drosophila) NM_019670 22.1 0.0016 24.2 0.0045
Evl Ena-vasodilator stimulated phosphoprotein NM_007965 21.3 0.1199 22.6 0.0043
Fmn1
* formin 1 NM_010230 22.5 0.0280 22.4 0.0478
Fyn Fyn proto-oncogene NM_001122893 1.4 0.1021 2.7 0.0362
Flnb filamin, beta NM_134080 25.3 0.0283 24.0 0.0385
Fscn1 fascin homolog 1, actin bundling protein NM_007984 21.5 0.0487 24.1 0.002
Gsn Gelsolin NM_146120 1.2 0.0496 2.4 0.0284
IQGAP2 IQ motif, GTPase actinvating protein 2 NM_027711 3.6 0.4092 14.0 0.0185
IQGAP3 IQ motif, GTPas- actinvating protein 3 NM_178229 22.1 0.0140 22.1 0.0987
Ivns1abp influenza virus NS1A binding protein NM_001039511 22.6 0.0134 22.1 0.0233
Lmo7 LIM domain only 7 NM_201529 23.7 0.0008 22.7 0.0104
Map2k1 mitogen activated protein kinase kinase 1 NM_008927 1.4 0.0781 2.2 0.0236
Map2k5 mitogen activated protein kinase kinase 5 NM_011840 1.3 0.1457 2.0 0.0045
Map3k1 mitogen activated protein kinase kinase kinase 1 NM_011945 1.1 0.5470 2.1 0.0028
Marcks Myristoylated alanine-rich kinaseC substrat NM_008538 21.6 0.0059 22.1 0.0059
Msn Moesin NM_010833 21.8 0.0012 22.4 0.0007
Mtss1 metastasis suppressor 1 NM_144800 1.7 0.2052 22.2 0.0114
Myh10 myosin, heavy polypeptide 10, non-muscle NM_175260 22.4 0.0770 24.0 0.0264
Myh9 myosin, heavy polypeptide 9, non-muscle NM_022410 22.3 0.0567 22.3 0.0558
Mylip myosin regulatory light chain interacting protein NM_153789 21.1 0.5508 22.2 0.0042
Myo18a myosin XVIIIa NM_011586 1.2 0.0760 2.9 0.0281
Myo1c myosin IC NM_001080775 22.6 0.0165 23.2 0.0135
Palld palladin, cytoskeletal associated protein NM_001081390 21.9 0.0531 23.1 0.0145
Plcb1 phospholipase C, beta 1 NM_019677 1.5 0.2930 4.4 0.0015
Plcb4 phospholipase C, beta 4 NM_013829 1.7 0.1110 3.2 0.0165
Rhoj ras homolog gene family, member J NM_023275 22.7 0.0256 27.5 0.0077
Rhou ras homolog gene family, member U NM_133955 1.2 0.3921 2.3 0.0257
Sorbs1 sorbin and SH3 domain containing 1 NM_009166 228.3 0.0496 215.4 0.0545
Tpm2 Tropomyosin 2, beta NM_009416 21.9 0.2948 242.1 0.0191
Tpm3 Tropomyosin 3, gamma NM_022314 21.4 0.1108 22.3 0.0069
Tpm4 tropomyosin 4 NM_001001491 21.4 0.1012 22.4 0.0165
Wasl Wiskott-Aldrich syndrome-like (human) NM_028459 1.0 0.7863 2.1 0.0008
List of genes differentially regulated (fold differences $2, p,0.05) which are structural or regulatory proteins of the actin cytoskeleton. Genes in italics were analyzed by
qRT-PCR; genes in bold changed significantly between MOSE-E and MOSE-L cells and those not in bold changed significantly between MOSE-E and MOSE-I cells.
*denotes genes that are already changed in MOSE-I and maintain these expression levels in MOSE-L.
doi:10.1371/journal.pone.0017676.t003
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cells with cytokeratins 7,8, and 19 verified by qRT-PCR (Table 5).
Immunostaining with a pan-cytokeratin antibody revealed that
MOSE-E cells have a well organized intermediate filament
network extending throughout the cells, whereas the
intermediate filament network in MOSE-L cells is composed of
short filamentous structures that do not radiate throughout the cell
in a organized manner (Figure 3A, last column). Well-defined
cytokeratin filaments were noted in only about 25% of MOSE-I
cells, with the remainder of cells displaying diffuse cytokeratin
staining with the limited organization reminiscent of MOSE-L
cells.
Comparison to archived human ovarian cancer
microarray data sets
In order to determine the relevance of the observed changes in
the cytoskeleton gene expression levels of our MOSE cell
progression model to human ovarian cancer, we evaluated
archived DNA microarray data sets which compared gene
expression levels in different established human ovarian cell lines
with normal ovarian surface epithelial cells as reference (see
Materials and Methods for a description of cell lines evaluated).
Although differential expression of cytoskeletal genes were not a
focal point in these human studies, approximately 50% of the actin
and focal adhesion associated genes listed in Table 2 as
significantly down-regulated during MOSE cell progression were
also significantly down-regulated in the human ovarian cell lines.
As shown in Table 6, there was a clear enrichment for significant
changes in the actin and focal adhesion associated genes. Using the
cumulative bionomial distribution, the estimated probability of
observing this many differentially expressed actin and focal
adhesion genes in the human studies by chance were 2.23610
26
and 1.87610
27, respectively, for the comparison with data from
Nagaraja et al. [21] and Iorio et al. [22]. In addition, comparative
analysis revealed that several additional actin binding genes listed
in Table 3 were significantly downregulated in the human ovarian
cancer cell lines. Of note, Marcks and Tpm2 were downregulated
by 10- and 23-fold respectively in aggressive ovarian tumor cells
compared to normal OSE. The overlap of differentially expressed
genes in the microtubule functional category did not reach
significance [21]. This may be a result of the comparatively small
changes in gene expression levels in this category. However, the
Ndn gene, which was 27 fold down-regulated in the MOSE cells,
was as much as 125 fold down-regulated in the human cancer cell
lines [21]. Together, these results suggest that changes in the
cytoskeleton are common to many ovarian cancer cell lines
independent of their histological type.
Changes in actin cytoskeleton regulation and
architecture during neoplastic progression
To determine the mechanisms of cytoskeletal deregulation
during MOSE malignant progression, we investigated the
expression levels and subcellular localization of several regulatory
proteins, including a-actinin, vinculin and focal adhesion kinase
(FAK). These proteins were chosen because of their involvement
in cytoskeleton regulation, cell motility, and cancer progression/
metastasis. a-actinin is involved in actin bundling by cross-linking
actin filaments and is part of the focal adhesion complex that links
the actin cytoskeleton to integrins [23,24]. The microarray results
indicated progressively decreasing a-actinin expression levels
which were confirmed by qRT-PCR (Table 2). a-actinin protein
levels were significantly decreased in both MOSE-I and MOSE-L
cells compared to MOSE-E cells (Figure 2A). A distinct co-
Figure 2. Levels of cytoskeleton and actin regulating proteins
in neoplastic progression. Whole cell extracts from MOSE-E (E, white
bars), MOSE-I (I, grey bars), and MOSE-L (L, black bars) cells were
subjected to Western blot analysis with antibodies directed against (A)
actin regulating proteins and (B) microtubule proteins. Expression
levels are expressed as percent MOSE-E levels normalization to
ribosomal protein L19 (RPL19) or c-tubulin for three biological
replicates done in duplicate 6 the standard deviation. A representative
blot from the three biological replicates is shown. *p# 0.01.
doi:10.1371/journal.pone.0017676.g002
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parallel to the leading edge was always readily apparent in MOSE-
E cells (Figure 3B). In MOSE-L cells, a-actinin appeared largely as
diffuse staining in the cytoplasm with considerably less evident co-
localiziation with actin filaments (Figure 3B, red). This was also
observed in MOSE-I cells (data not shown). Confocal microscopy
Figure 3. Organization of the cytoskeleton and localization of actin regulating proteins with neoplastic progression. (A)
Immunofluorescent staining of MOSE-E, MOSE-I and MOSE-L cells to visualize actin filaments (phalloidin, green), a- tubulin (2
nd column), b- tubulin
(3
rd columns), or cytokeratin (4
th column) along with the nucleus (blue, DAPI). (B and C) Triple staining of MOSE-E and MOSE-L cells with DAPI (blue),
phalloidin (f-actin, green), and antibodies against a-actinin (red, B) or vinculin (red, C). The confocal images shown are 0.6 mm apart within the cell,
with image 1 starting at the base of the cell and image 2 towards the top of the cell. Co-localization appears as yellow in merged and confocal
images. (D) Triple staining of MOSE-E and MOSE-L cells with DAPI (blue), antibody against FAK (green), and antibody against FAK phosphorylated
tyrosine 861 (red, FAK
Y861). Yellow in merged image indicates co-localization. (Original magnification X600)
doi:10.1371/journal.pone.0017676.g003
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filaments and disorganized actin found in MOSE-L cells
(Figure 3B, confocal images and inset).
In addition to actin filament bundling, a-actinin acts as a
platform to mediate protein-protein interactions including those
involved in forming and maintaining focal adhesions [23,24].
MOSE cells had variable levels of gene products known to
associate with or modulate focal adhesions (Table 2, Focal
Adhesions). Also, a number of gene products directly associate
with a-actinin to modulate focal adhesions (zyxin, vinculin,
integrin b1 and b2) or regulate actin (palladin and syndecan).
Changes in mRNA levels of several of these genes were confirmed
by qRT-PCR (Table 2). Importantly, genes associated with cancer
progression (i.e., Itgb2, Itgb5, paxillin, fyn) displayed increased
expression, whereas those thought to suppress progression (i.e.,
vinculin, gravin) exhibited decreased levels of expression com-
pared to MOSE-E cells.
Vinculin, which binds actin and is part of the focal adhesion
complex linking actin to integrins, exhibited both reduced mRNA
(Table 2) and protein levels (Figure 2A) during malignant
progression. To visualize potential alterations in subcellular
localization, MOSE cells were immunostained for both F-actin
and vinculin (Figure 3C). In MOSE-E cells, vinculin co-localized
to the ends of actin bundles, forming well-defined focal adhesion
structures similar to that observed for non-transformed epithelial
cells. In contrast, vinculin staining was largely diffuse and only
marginally co-localized with actin fibers in the MOSE-L cells.
Inherently, the focal adhesion-like structures in MOSE-L cells
were less defined and more punctate. Confocal microscopy
revealed that vinculin was distributed throughout the cytoplasm
of MOSE-L cells and did not appear to associate directly with the
disorganized actin, (Figure 2C, confocal images). Similar vinculin
staining patterns were observed in 90% of the MOSE-I (data not
shown), suggesting that aberrant vinculin subcellular localization is
an early event as cells transition from MOSE-E to MOSE-I.
The primary component of focal adhesions, FAK, did not
exhibit significant changes in mRNA levels during MOSE
progression (Table 2). However, FAK protein levels were
significantly elevated in both MOSE-I and –L cells compared to
MOSE-E (Figure 2A). To determine if there is also a change in
FAK activity and localization, MOSE cells were immunofluores-
cently stained for total FAK (red) and FAK phosphorylated on
tyrosine861 (FAK-P
Y861, green) (Figure 3D). Of note, phosphor-
ylation of FAK on tyrosine Y
861 by Src, one of two residues
phosphorylated by Src, contributes to cell migration [25,26]. As
shown in Figure 3D, FAK was only marginally associated with the
membranes of MOSE-L cells compared to the bright punctate
staining at the cell periphery of MOSE-E, but was rather
diffusively distributed throughout the cytosol. Overall, there was
very little punctate staining of FAK at the periphery of MOSE-L
cells. Interestingly, the peripheral total FAK co-localized with the
active FAK-Y
861, suggesting that peripheral FAK is active in both
MOSE-E and –L cells (Figure 3C, merge). Since FAK staining
requires MeOH fixation, confocal microscopy did not provide
conclusive results as to the co-localization of diffuse total FAK and
pFAK-Y
861 observed in MOSE-L cells. Thus, it is unclear whether
diffuse pockets of disorganized actin and total FAK contribute to
the reduced formation of focal adhesions observed in MOSE-L
cells.
Neoplastic cytoskeleton changes influence signal
transduction pathways
The cytoskeleton plays an important role in tumor cell
progression and events such as migration and invasion, allowing
the cells to adapt and survive in different microenvironments;
compounds that regulate cytoskeleton organization have been
used as cancer therapeutics [27]. On the other hand, the
organization of the cytoskeleton affects cellular organization,
adhesion complexes and polarity, and vesicular transports. As
noted above, the subcellular localization of proteins associated
with focal adhesions displayed aberrations concomitant with the
disorganized state of the cytoskeleton. This may allow the tumor
cells to bypass cellular homeostatic control mechanisms by
diverting signaling proteins to different locations, thereby changing
the availability of binding partners or substrates, which may
modify signal transduction pathways. Since aberrant signaling is a
sign of malignancy [28], immunostaining for global tyrosine and
serine phosphorylated proteins was used as a general gauge of
signal transduction pathway organization and function.
Tyrosine phosphorylation, an indicator of receptor and non-
receptor tyrosine kinase activity, plays a critical role in cancer cells,
regulating proliferation, differentiation, and metabolism; 51 of the
90 tyrosine kinases have been implied in cancer (see recent review
[28]. As shown in Figure 5A (top panel), MOSE-E cells showed a
distinct phospho-tyrosine staining pattern highly reminiscent of
focal adhesions at the cell periphery, with prominent co-
localization evident at the ends of actin fibers and only marginal
staining in the cytosol. In contrast, phosphotyrosine immunostain-
ing did not co-localize strictly with actin fiber ends, presumably
focal adhesions, in MOSE-L cells and was also readily apparent in
the cytosol and in perinuclear regions (Figure 5A, bottom panel).
Phosphoserine immunostaining, an indicator of downstream
signaling and G-protein coupled receptor activity, appeared as
organized punctae along filament-like structures radiating from
the nucleus in MOSE-E cells. These did not co-localize with actin
or cytokeratin; although the staining pattern suggested a co-
localization with tubulin, this could not be confirmed since our
tubulin and phosphoserine antibodies are produced in the same
species, not allowing for double staining (Figure 5A, top panel). In
MOSE-L, immunostaining for phosphoserine also appeared as
punctae but were less organized (Figure 5A, bottom panel). As
expected due to its role in the regulation of the splicing machinery,
phosphoserine staining was detected in the nuclei of both MOSE-
E and MOSE-L cells.
Figure 4. Quantitation of filamentous actin in pre-malignant
and malignant MOSE cells. Equal numbers of MOSE-E or MOSE-L
cells where plated. After 48 hours, cells were fixed with paraformalde-
hyde and stained with phalloidin conjugated with Alexa Fluor
488. The
phalloidin was solubilized with MeOH and fluorescence was deter-
mined. Data were normalized to cell number and presented as the
mean relative fluorescent units (RFU) per cell 6 the standard deviation.
*p # 0.01.
doi:10.1371/journal.pone.0017676.g004
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cytoskeleton changes during the progression of MOSE-E to
MOSE-L cells could lead to an incorrect localization/scaffolding
of proteins and change signal transduction pathways, we analyzed
integral signaling proteins that have also been implied in ovarian
cancer development: protein kinase C b II (PKCbII) and
adenomatous polyposis coli (APC). PKCbII is a member of the
serine/threonine kinase family with a broad spectrum of
intracellular targets and, thus, a central signaling intermediate in
a multitude of signaling pathways. PKCbII is involved in the
regulation of proliferation, apoptosis but also promotes angiogen-
esis, invasion and progression [29,30]. In MOSE-E cells, PKCbII
(Figure 5B, red) appeared as distinct punctae throughout the
cytoplasm, co-localizing with actin stress fibers and actin at the
leading edge (Figure 5B, merge). In contrast, PKCbII in MOSE-L
cells (Figure 5B, bottom panel) was more diffuse and rarely co-
localized with actin fibers (specific images of cells showing actin
fibers were chosen). PKCbII immunostaining in MOSE-I cells
displayed a mixed pattern with commonalities between that
observed for both MOSE-E and MOSE-L cells (data not shown).
Table 4. Differentially Expressed Microtubule and Microtubule Associated Genes in MOSE cell stages.
Gene Symbol Gene Name Accession Number I/E p-val L/E p-val
Microtubule
Tuba4a tubulin, alpha 4A NM_009447 1.5 0.0301 22.2 0.0146
Tubb2a tubulin, beta 2a NM_009450 21.2 0.4725 23.5 0.0007
Tubb2b tubulin, beta 2b NM_023716 22.8 0.0200 23.3 0.0144
Tubb2c tubulin, beta 2c NM_146116 1.2 0.2601 22.1 0.0261
Tubb3 tubulin, beta 3 NM_023279 1.5 0.1902 23.0 0.0362
Tubb6 tubulin, beta 6 NM_026473 21.2 0.0437 24.7 0.0013
Microtubule Binding and Regulation
Aspm
+ asp (abnormal spindle)-like NM_009791 21.7 0.0467 23.0 0.0300
Cenpe
+ centromere protein E NM_173762 22.2 0.0246 23.7 0.0171
Ckap2
+ cytoskeleton associated protein 2 NM_001004140 1.1 0.3932 22.2 0.0324
Ckap2l cytoskeleton associated protein 2-like NM_181589 1.0 0.2245 22.8 0.0050
Ckap4 cytoskeleton-associated protein 4 NM_175451 21.7 0.0290 23.0 0.0077
Dnm2 dynamin 2 NM_001039520 1.7 0.2847 4.4 0.0049
Dync1i1 dynein cytoplasmic 1 intermediate chain 1 NM_010063 1.4 0.4035 6.1 0.0450
Incenp
+ inner centromere protein NM_016692 1.1 0.1875 22.1 0.0379
Jub
+ Ajuba NM_010590 23.6 0.0390 23.2 0.0451
Kif1b kinesin family member 1B NM_008441 21.9 0.0304 22.3 0.0195
Kif18a
+ kinesin family member 18A NM_139303 21.2 0.2028 22.8 0.0062
Kif20a
+ kinesin family member 20A NM_009004 1.2 0.1513 22.7 0.0331
Kif21a kinesin family member 21A NM_016705 1.5 0.2060 2.4 0.0334
Kif22
+ kinesin family member 22 NM_145588 1.0 0.2291 22.7 0.0178
Kif23
+ kinesin family member 23 NM_024245 21.2 0.0970 23.4 0.0082
Kif26b kinesin family member 26B NM_001161665 1.0 0.9068 23.9 0.0102
Kif2c kinesin family member 2C NM_134471 21.2 0.0918 22.9 0.0211
Kif4
+ kinesin family member 4 NM_008446 21.4 0.0966 22.1 0.0306
Klc1 kinesin light chain 1 NM_008450 21.4 0.0455 22.6 0.0009
Klc4 kinesin light chain 4 NM_029091 1.3 0.3611 3.1 0.0015
Lats2
+ large tumor suppressor 2 NM_015771 23.4 0.0035 22.7 0.0058
Mtap6 microtubule-associated protein 6 NM_010837 23.0 0.0012 215.7 0.0004
Ndn necdin NM_010882 23.7 0.0124 226.8 0.0017
Ninl* ninein-like NM_207204 22.6 0.0068 22.2 0.0029
Pea15a phosphoprotein enriched in astrocytes 15A NM_011063 21.3 0.2698 22.9 0.0179
Prc1
+ protein regulator of cytokinesis 1 NM_145150 21.4 0.0245 22.6 0.0158
Shroom3 shroom family member 3 NM_015756 21.2 0.3917 2.8 0.0115
Tbcel tubulin folding cofactor E-like NM_173038 1.2 0.1501 3.5 0.0292
Vav2 vav 2 guanine nucleotide exchange factor NM_009500 22.1 0.0226 24.0 0.0062
List of genes differentially regulated (fold differences $2, p,0.05) which are structural or regulatory proteins of the microtubule network. Genes in italics were analyzed
by qRT-PCR and those in bold were validated to change significantly.
*denotes genes that are already changed in MOSE-I and maintain these expression levels in MOSE-L, + denotes genes that have products involved in chromosome
congression, segregation, and/or cytokinesis.
doi:10.1371/journal.pone.0017676.t004
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performed to analyze PKCbII association with cytoskeletal
components. Total PKCbII levels increased more than 4-fold in
MOSE-L compared to MOSE-E cells (p,0.001) (Figure 6B). This
correlates well with the role of overexpressed PKCbII in cancer
progression which has led to the development of specific PKCbII
inhibitors that alone or in combination with conventional drugs
suppressed ovarian cancer cell growth [31]. The percentage of
total PKCbII in the cytoskeletal fraction changed from 39% in
MOSE-E cells to 9.5% in MOSE-L cells (Figure 6A).
Table 5. Differentially Expressed Intermediate Filaments and Associated Genes in MOSE cell stages.
Gene Symbol Gene Name Accession Number I/E p-val L/E p-val
Intermediate Filaments
Krt7 keratin 7 NM_033073 211.3 0.0006 225.8 0.0003
Krt8 keratin 8 NM_031170 1.2 0.0249 22.7 0.0035
Krt14 keratin 14 NM_016958 23.7 0.0034 2721.9 0.0006
Krt19 keratin 19 NM_008471 21.3 0.2914 22.2 0.0437
Lmna lamin A NM_001002011 21.4 0.0189 22.6 0.0043
Lmnb1 lamin B1 NM_010721 21.8 0.0860 22.8 0.0581
Intermediate Filament Binding
Eppk1 epiplakin 1, similar to Epiplakin NM_144848 26.3 0.0228 2.2 0.0343
List of genes differentially regulated which are structural or regulatory proteins of the intermediate filament network. Genes in italics were analyzed by qRT-PCR and
those in bold were validated to change significantly.
doi:10.1371/journal.pone.0017676.t005
Table 6. Comparison of differentially expressed cytoskeleton and regulatory genes with archived array data sets comparing
established human ovarian cell lines with normal ovarian surface epithelium.
Gene Illumina Rank
a Fold change
b p-value Affymetrix Rank
a Fold change
b p-value
ACTA1 x x x x
ACTA2 1.8% 27.7 2.00E-06 0.6% 258.8 5.00E-05
ACTG1 5.7% 21.8 6.00E-05 x x
ACTG2 x x x x
ACTN1 2.7% 22.6 5.00E-06 0.5% 24.0 2.00E-05
FBLIM1 1.4% 22.3 8.00E-07 0.8% 28.3 9.00E-05
ITGA7 x x 5.3% 25.0 2.00E-02
ITGAV x x 4.8% 22.4 1.00E-02
ITGB1 x x 0.8% 25.3 1.00E-04
ITGB2 x x x x
ITGB5 1.6% 26.3 1.00E-06 0.7% 24.5 5.00E-05
LASP1 x x x x
MARCKS 0.5% 210.2 3.00E-08 1.4% 27.1 5.00E-04
NCK2 5.5% 21.9 6.00E-05 x x
PARVA 9.4% 21.8 3.00E-04 2.9% 24.5 4.00E-03
PXN x x x x
TGFB1I1 7.3% 26.7 1.00E-04 x x
TNS1 7.8% 22.9 2.00E-04 4.3% 27.1 1.00E-02
TPM2 0.03% 223.1 1.00E-11 1.9% 27.0 1.00E-03
VCL 8.1% 22.0 2.00E-04 x x
ZYX 8.7% 21.9 2.00E-04 1.3% 23.6 4.00E-04
NDN 0.5% 2124.6 3.00E-11 0.3% 223.7 5.0E-06
Binomial probability 1.86E-07 1.04E-08
The expression levels of genes changed in the MOSE model were compared to changes determined in established human cell lines reported by Nagaraja et al.
[21](Illumina data sets) and Iorio et al. [22](Affymetrix data sets). x denotes non-significant changes, or expression levels below detection limit. Only ITGB5 levels
changed in the opposite direction than the MOSE cells. a) Rank refers to the percentile rank when the human microarray data sets are sorted by increasing p value. b)
Mean Fold change in gene expression of cancer cell lines compared to normal human OSE data sets.
doi:10.1371/journal.pone.0017676.t006
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matous polyposis coli (APC), a scaffolding protein that regulates b-
catenin metabolism [32] but is also involved in a broad range of
other, b-catenin- independent processes such as regulation of
microtubule assembly and bundling [33]. APC mutations contribute
significantly to colon carcinogenesis [34] but also have been implied
in ovarian cancer development [35,36]. Approximately 50% of
MOSE-E cells showed substantial APC staining in the nucleus while
only a small percentage of MOSE-I cells and none of the MOSE-L
cells displayed nuclear staining. Cells with nuclear APC showed very
little cytosolic staining (Figure 5C). APC appeared punctuated in the
cytosol of all MOSEcells(Figure 5C,red). Mostof the cytosolicAPC
in MOSE-E and MOSE-I cells appeared to co-localize with actin
fibersespeciallyonthe cellperiphery (figure 5B, top panel); however,
this was not observed in MOSE-L cells.
Discussion
In the present study, we have identified genes and their
functional categories that were altered as MOSE-derived cells
transition from an early, pre-malignant, to a highly malignant
stage. Our gene expression profiles from the transitional stages of
MOSE cells displayed statistically significant changes in cell cycle,
proliferation, metabolism and other functional categories that
corresponded well with many of the morphological changes and
biological behaviors observed in our progressive MOSE model,
including the loss of contact inhibition, resistance to anoikis, the
ability to form colonies in soft agar, and the capacity to form
invasive tumors in vivo in an immunocompetent host [12]. While
many of the gene expression changes may be applicable to other
cancer models, the early stage dysregulation of the cytoskeleton
Figure 5. Influence of actin disorganization on localization of signaling proteins PKCbII and APC. (A) Immunofluorescent staining for
DAPI (blue), phosphotyrosine (red, pTyr), and phalloidin (green, f-actin) or DAPI (blue), phosphoserine (red, pSer), with either phalloidin (f-actin,
green) or cytokeratin (green). (B and C) Triple staining of MOSE-E and -L cells with DAPI (blue), phalloidin (f-actin, green) and PKCbII (red, B) or APC
(red, C) antibodies. (Original magnification X600).
doi:10.1371/journal.pone.0017676.g005
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cancer progression.
Together, our data reflects many of the changes observed in
established human ovarian cancer and further identifies several
early events involved in neoplastic progression that may represent
early targets for therapeutic intervention.
The substantial gene expression changes in the cytoskeleton
category led us to focus on both key cytoskeleton proteins and their
regulators to further delineate their global role in neoplastic
transformation. Of note, stepwise dysregulation of the cytoskeleton
has not been studied in depth for the early events in ovarian
cancer. During the malignant progression of the MOSE cells, the
microfilament, microtubule and intermediate filament systems
became sequentially disorganized, highlighted by i) distinct protein
level changes, ii) the significant loss of polymerized F-actin, and iii)
the decreased capacity for formation of focal adhesions. Interest-
ingly, the global subcellular distribution pattern of proteins
phosphorylated on serine or tyrosine residues changed as MOSE
cells progressed to a more malignant state, suggesting that
signaling pathways were also becoming progressively altered. This
may be partly due to the aberrant subcellular localization of
proteins resulting from changes to cytoskeletal architecture. In
support of the latter, changes affecting PKCbII and APC
expression and localization, integral signaling intermediates
associated with cancer development, correlated well with cyto-
skeleton alterations.
Cytoskeleton and cytoskeleton-regulating proteins
Actin filaments, along with their associated proteins, are
essential for cellular morphology, motility and migration, phago-
cytosis, vesicular movement, cytokinesis, and molecular transport
between the plasma membrane and the nucleus [15]. Changes
affecting actin cytoskeleton architecture were early events in the
transitional progression of our MOSE-derived cells as most of the
changes in gene expression and protein levels were readily evident
in the MOSE-I cells, an intermediate transitional stage that
already has acquired limited tumor-forming capacity. Microtubule
organization, essential for cell division, cell migration, vesicle
transport and cell polarization [37] was altered progressively
during malignant progression culminating in a highly disorganized
state in malignant MOSE-L cells. Of particular note is that the
observed cytoskeletal alterations during MOSE cell progression
have also been reported in several established human ovarian
cancer lines that represent late stage aggressive disease. A
comparison of our results to microarray data sets from established
human ovarian cancer cell lines and benign or normal OSE as a
reference [21,22] demonstrated a highly significant overlap in the
changes of cytoskeleton and regulatory genes (see Table 6).
Furthermore, in a recent proteomic study of human ovarian
cancer, 21 of the 37 proteins found to be differentially expressed
between low- and high-grade ovarian cancer cell lines (TOV-81D
and TOC-112D, respectively) were involved in cytoskeleton
organization, cell adhesion and motility [38]. Similar changes in
genes overrepresented in these functional categories were observed
by proteomic comparison of several established and widely used
ovarian cancer cell lines; it was concluded that these gene changes
were not associated with a specific sub-type of ovarian cancer but
rather with the cells’ aggressive and invasive behavior [39].
Importantly, our data reveal a stepwise accumulation of genetic
changes affecting the actin cytoskeleton that are not readily
apparent when analyzing human ovarian cancer samples, which
are largely representative of late stage disease. Together, these
data suggest that the changes in the actin cytoskeleton are a
common event in ovarian cancer cells and not restricted to a
specific sub-type of ovarian cancer. Thus, these genes and gene
products may represent potential early targets for chemothera-
peutic intervention against several types of ovarian cancer.
Reciprocal or coordinated regulation of cytoskeleton compo-
nents, specifically microtubules and the actin cytoskeleton, is
becoming more apparent [40,41,42]. Our data demonstrating
early, more drastic changes in the actin cytoskeleton validate these
observations and suggest that the early disorganization of the actin
cytoskeleton may be a key element that facilitates further
dysregulation of the cytoskeleton in ovarian cancer. Hence, actin
and its regulatory and associated proteins may be better
therapeutic targets in ovarian cancer. This hypothesis is supported
by recent observations demonstrating that interference with actin
dynamics is more effective than microtubule disturbance in
inhibiting human ovarian cancer cell motility [43], and stabiliza-
tion of the actin cytoskeleton can be achieved by re-introduction of
actin-binding proteins such as calponin [44]. Interestingly,
calponin re-expression in ovarian cancer cells also significantly
reduced peritoneal dissemination [45].
Prominent stress fibers have been demonstrated in more
stationary cells and are thought to inhibit motility, whereas
changes in cytoskeleton regulatory proteins have been closely
associated with increased cell motility and invasion [46]. Our
studies show the sequential loss of stress fibers during MOSE
progression. This may be associated with the aberrant expression
and localization of cytoskeleton regulators such as vinculin, FAK,
and a-actinin, since these regulators form complexes with other
membrane proteins such as integrins that together generate signals
to regulate proliferation and migration of normal and tumor cells
[26,47]. We have reported the increase in cell proliferation during
MOSE progression [12] that correlates well with the changes in
Figure 6. PKCbII protein levels and interactions with cytoskel-
eton. Equal amounts of protein from MOSE-E and MOSE-L was
fractionated into 1% triton X-100 soluble and non-soluble (pellet)
portions and analyzed by western blot analysis (A). Protein levels are
the mean of three measurements expressed as percent of the total
PKCbII protein with standard deviations #1.5% for all samples,
normalized by cell number. (B) Total protein levels (soluble + pellet)
(mean of three measurements) are expressed as percent of MOSE-E
levels. * p,0.001.
doi:10.1371/journal.pone.0017676.g006
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a- and b-tubulin, keratin 7, and other cytoskeleton regulators has
been reported in drug-resistant ovarian tumors [48], indicating
that dysregulation of the cytoskeleton may also contribute to multi-
drug resistance. Interestingly, FAK inhibition augmented doc-
etaxel-mediated apoptosis in ovarian cancer cells [49,50],
suggesting that the effects of the cytoskeleton and its regulators
are not limited to regulation of cell morphology, adhesion and
motility. Thus, the cytoskeleton and its regulators -especially of the
actin cytoskeleton in early stages- may be effective chemothera-
peutic targets as has been already shown for the microtubule
system [27,51].
It should also be noted that additional actin-binding proteins
(see Table 3) such as tropomyosin 2 were found to be significantly
down-regulated in MOSE-L cells. Though tropomyosin function
is less defined in non-muscle cells, an increase in actin stiffness,
protection from branching due to cofilin activity, and formation of
lamellipodia has been reported (see recent review [52]). In cancer,
frequent changes in tropomyosin expression levels have been
noted and loss of tropomyosin has been associated with the switch
from a dormant to rapidly growing tumor [53]. Down-regulation
of tropomyosin 2 via epigenetic silencing in human ovarian cancer
has been reported [54] and recent results in our laboratories using
59aza deoxycytidine treatment suggest that tropomyosin 2 as well
as a-actinin and vinculin are epigenetically silenced in MOSE-L
cells (unpublished observations). We have already demonstrated
that promoter methylation of the E-cadherin gene results in its
silencing during MOSE progression [12]. Future studies will help
define at what stage this epigenetic silencing of actin regulatory
genes occurs and if these specific genes are potential targets for
chemotherapeutic interventions.
Signal Transduction
Post-translational modifications including protein phosphoryla-
tion determine cellular responses and functions. Changes in the
equilibrium of the antagonistic kinase and phosphatase activities,
especially on tyrosine residues, have been described in many
cancers as a result of the oncogenic activation of receptor or non-
receptor tyrosine kinases or the inhibition of protein tyrosine
phosphatases (e.g., EGFR, Her-2neu, Src, Abl, PTPs) [28].
Changes in G-protein coupled receptors affect the phosphoryla-
tion of serine residues and subsequently a multitude of signaling
pathways. An increase of tyrosine phosphorylated proteins and
altered intracellular localization of both tyrosine or serine
phosphorylated proteins during the progression in our MOSE
model suggest the relocalization of signaling intermediates may be
associated with changes in cellular properties and functions. While
it was not within the scope of this study to identify these proteins
and characterize affected signaling pathways and downstream
events, we have identified an aberrant expression and localization
of two important signaling molecules, PKCbII and APC.
PKCbII is critically involved in cancer of several organs
including the ovaries [9,29]. Upon activation, PKCbII is
translocated to the membrane and pericentrosomal regions
[55,56] which requires the presence of a well-organized actin
cytoskeleton [57]. PKCbII can directly bind to actin, which in turn
modulates its substrate specificity via determination of substrate
proximity [58], suggesting that the actin cytoskeleton controls the
target substrate and, therefore, the regulated signaling pathways
[57]. One could speculate that the overexpression and sequestra-
tion of activated PKCbII during neoplastic progression provides a
survival mechanism, or its proximity to other signaling compo-
nents may serve to provide the cell with a constitutive endogenous
signaling compartment, stimulating cell survival, migration and
invasion. The overexpression and pericentrosomal aggregation of
PKCbII observed in MOSE-L cells concurrent with actin
microfilament disorganization, taken together with previous
findings, suggests that the two events may be inherently linked.
Progression to the MOSE-L stage in our model was
accompanied by the presence of podosome-like structures
throughout the cytoplasm of the cell. PKC activation is associated
with the formation of podosomes, which may be immature forms
of invadopodia [18,59]. It also modulates the distribution of F-
actin and can lead to a dissociation of vinculin from focal
adhesions in transformed cells [60]. Hence, the podosomes-like
structures observed in MOSE-L cells may be the indirect result of
over-expressed or sequestered PKCbII, but this needs to be
investigated further.
Concurrent with the actin cytoskeleton disorganization, aber-
rant localization of APC was observed during progression to the
malignant MOSE-L phenotype. APC serves as a negative
regulator of Wnt signaling, acting as a key tumor suppressor gene
that is often mutated in colon cancer [34] but has also been
implicated in ovarian cancer development [36]. APC is a
multifunctional protein, influencing both microtubule assembly
and bundling [61] as well as actin polymerization and cell polarity
[62]. Recent studies suggest that APC may act in a more regulated
fashion by i) direct association with microtubules [63], ii) binding
cytoskeleton regulating proteins including IQGAP1 [62,64] and
iii) interacting with intermediate filaments [65], all of which
suggest that the cytoskeletal architecture is critical for APC
localization [66]. Thus, the early changes in the cytoskeleton in
our MOSE cell system may have a direct impact on the subcellular
localization of APC influencing its function. Interestingly, in
normal colon cells, APC is strongly localized in the nucleus while
appearing increasingly in the cytoplasm in colon carcinoma [34].
APC shuttles between nucleus and cytoplasm, sequestering b-
catenin to induce degradation in the cytoplasm or dampen b-
catenin mediated transcriptional activity in the nucleus [67].
However, the binding to DNA, base excision DNA repair proteins,
and phosphotyrosine phosphatases indicates other, yet to be
determined functions of APC in the nucleus. The loss of full-length
APC activates a DNA demethylase in colon cells and increased the
expression of genes that maintain an undifferentiated cellular state
[68]. These observations together with the loss of APC during
progression of our MOSE-derived cells strongly support a tumor-
suppressing effect of nuclear APC.
In summary, gene expression profiling during neoplastic
progression of MOSE cells revealed that cytoskeleton associated
genes were significantly impacted as cells transitioned from a
benign to a malignant stage. Distinct actin regulatory genes were
dysregulated at early stages in ovarian cancer progression with
microtubule and intermediate filament alterations following at
later stages. Our data support the concept of cross-talk between
actin, tubulin and intermediate filament regulatory mechanisms.
We provide further evidence that progressive disruption of the
cytoskeleton architecture plays a pivotal role in subcellular
organization of signaling intermediates, particularly with respect
to coordinated signal transduction events. Thus, cytoskeleton
dysregulation may influence trafficking of proteins and vesicles
within the cell, changing the proximity of substrates and enzymes
that subsequently lead to aberrant downstream signaling pathways
and cellular responses. Finally, our data supports the hypothesis
that structural rearrangements of the cytoskeletal architecture are
crucial for neoplastic progression, conveying signals from the
extracellular matrix to the nucleus that allow cancer cells to adapt
to their microenvironment via transcription factor activation and
subsequent change of gene expression (see recent review [69]).
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in human ovarian cancer and therefore validate the use of our
model for future mechanistic studies to further define how
cytoskeletal organization modulates the subcellular localization
of cancer promoting signaling pathways.
Materials and Methods
Cell Culture
The MOSE cell model utilized in this study was developed and
characterized as previously described [12]. MOSE cells were
classified into early (MOSE-E, passages 5–20), intermediate
(MOSE-I, passages 60–80), and late (MOSE-L, passages 120–
180) stages based on ranges of passage number that displayed
similar growth rates, anchorage independent growth efficiencies in
soft agar, in vivo tumor formation, and aneuploidy. MOSE cell
lines were routinely maintained in DMEM high glucose medium
(Invitrogen, Carlsbad, CA) supplemented with 4% fetal bovine
serum (Hyclone, Logan, UT), 100 mg/ml each of penicillin and
streptomycin, 5 mg/ml insulin, 5 mg/ml transferrin, and 5 ng/ml
sodium selenite (Invitrogen, Carlsbad, CA). For RNA and protein
collection, cells were seeded in 100 mm dishes at 0.5-2610
6 cells
and grown for 1–2 days (60–80% confluency).
Gene Chip Micoarrays and Data Analysis
Biological replicate RNA samples for early (passage 13, 14, and
15), intermediate (63, 71, and 73), and late (136, 142, and 143)
passages were isolated using the RNeasy Kit according to the
manufacturers instructions (Qiagen, Valencia, CA) and treated with
ribonuclease-free deoxyribonuclease I (Qiagen, Valencia, CA). The
RNA samples were submitted to the Virginia Bioinformatics
Institute (VBI) Core Laboratory Facility (CLF) gene expression
unit for microarray analysis. At VBI CLF the RNA samples were
assayed on the Agilent 2100 BioAnalyzer for qualitative assessment
and quantification. cRNA was hybridized to GeneChip Mouse
Genome 430 2.0 Arrays (Affymetrix, Santa Clara, CA) containing
45,102 oligonucleotide probe sets representing over 18,000 known
genes. We utilized MicroArray Suite 5.0 (Affymetrix, Santa Clara,
CA)to process rawmicroarraydata. Data valueswerenormalizes to
a trimmed mean of 500 units to allow inter-GeneChip comparisons.
Excel Spreadsheet software(Microsoft,Silicon Valley, CA)was used
to obtain fold change and and t-test p-values for the pairwise
comparisons. After filtering for a maximum signal intensity greater
than 500 fluorescent units and significant differences between early
and late passages of greater than 2 fold (p#0.05), data was analyzed
for over-represented gene ontology categories using the Gene Trail
Program [13,70](http://genetrail.bioinf.unisb.de/index.php) and
Onto-tools Pathway Express (http://vortex.cs.wayne.edu/projects.
htm#Onto-Express) [71,72]. Comparison of MOSE cells with
human gene expression data was performed using the Gene
Expression Omnibus (GEO) Illumina microarray data sets for a)
Normal OSE cells and 10 ovarian cancer cell lines (OVAS, SMOV-
2, KK, OVSAYO, RMG-1, OVMANA, OVISE, TOV-21G, ES-
2, and OVTOKO) Accession number GSE16568 [21] and b)
Affymetrix microarray data sets using Normal OSE cells and 6
additional ovarian cancer cell lines (SKOV3, OVCAR3,
OVCA432, OVAW42, IGROV1, and CABA) Accession number
GSE19352 [22].
Real-time Polymerase Chain Reaction PCR (qRT-PCR)
Total RNA was extracted from biological replicate samples as
described above. 500 ng of total RNA was reverse-transcribed
using the ImProm-II Reverse Transcription System (Promega,
Madison, WI) with random hexamer and oligo-dT primers
according to the manufacturer’s instructions. Quantitative Real-
time Polymerase Chain Reaction (qRT-PCR) was performed on
5 ng of cDNA using gene specific primers designed using Beacon
Design software (Palo Alto, CA) and SensiMix Plus Sybr
mastermix (Quantace, Taunton, MA) in a 15 mL reaction volume.
qRT-PCR was performed for 42 cycles at 95uC for 15 seconds,
56–58uC for 30 seconds, and 72uC for 15 seconds, preceded by a
10 minute incubation at 95uC, on the ABI 7900HT Fast Real-
Time PCR System (Applied Biosystems, Foster City, CA). Melt
curves were performed to insure fidelity of the PCR product. The
DDCt method [73] was used to determine fold difference and the
student T-test was utilized to ascertain significance.
Cell Fractionation
Cells were grown in 100 mm tissue culture dishes as described
above and cell fractionated essentially as described by Blobe et al.
[58]. Briefly, cells were washed in PBS and lysed in 1% Triton X-
100 solubilization buffer (15 mM Tris, pH 7.5, 120 mM NaCl,
25 mM KCl, 1% (v/v) TritonX-100, and Complete Mini Protease
Inhibitor Cocktail (Roche, Indianapolis, IN)). Samples were
incubated on ice for 30 minutes. Proteins concentrations were
determined using a bicinchoninic acid protein assay kit (Pierce
Biotechnology, Rockford, IL) and equal amounts of protein where
separated into cytosol and cytoskeleton fractions by centrifugation
at 100,0006g for 1 hour. Pellets (cytoskeleton fractions) were
resuspended in 2X Laemmli buffer. Cytosol fractions (supernatant)
were concentrated by precipitation with an equal volume of 20%
(w/v) trichloroacetic acid for 30 min on ice, pelleted, washed with
ice-cold acetone, dried, and resuspended in 2X Laemmli buffer. If
necessary, residual trichloroacetic acid was neutralized with the
addition of 1M Tris, pH 8. Cell protein fractions were then
subjected to western blot analysis as described above. Densito-
metric quantitation of relative band intensity was performed using
the NIH Image J program and normalized to cell number for total
PKCbII levels.
Western Blot Analysis
Cells were grown in 100 mm tissue culture dishes as described
above, lysed with RIPA buffer [20 mM Tris-HCl pH 7.5, 1 mM
EDTA, 150 mM NaCl, 1% Triton X-100, 0.5% Na-Deoxycho-
late, and 0.5% SDS, plus Complete Mini Protease Inhibitor
Cocktail (Roche, Indianapolis, IN)], homogenized using a 22-
gauge needle, and insoluble debris was cleared by centrifugation
(15,000 g) for 20–30 minutes. Protein concentrations were
determined using a bicinchoninic acid protein assay kit (Pierce
Biotechnology, Rockford, IL). Proteins (10–20 mg/lane) were
separated on 12–15% SDS polyacrylamide gels and transferred
to a PVDF membrane (BioRad, Hercules, CA). PVDF membranes
were blocked with 5% non-fat milk in wash buffer [10 mM Tris-
HCl pH 7.5, 150 mM NaCl, 0.05% Tween-20]. Blots were
immunostained with mouse monoclonal antibodies to total actin,
vinculin, a-tubulin, b-tubulin, and c-tubulin (Sigma, St. Louis,
MO); Focal Adhesion Kinase (Upstate/Millipore, Billerica,
Massachusetts); a–actinin (Abcam, Cambridge, MA); PKCbII
and APC (Santa Cruz Biotechnology, Santa Cruz, CA). After
incubation with horseradish peroxidase-conjugated secondary
antibodies (Sigma, St. Louis, MO), SuperSignal West Femto
Maximum Sensitivity Substrate (Thermo Fisher/Pierce Biotech-
nology, Inc., Rockford, IL) was used to visualize protein bands on
the Chemidoc (Bio-Rad, Ventura, CA). Densitometric quantita-
tion of relative band intensity was performed using the NIH Image
J program and normalized to relative optical units of ribosomal
protein L19 (RPL19) or c–tubulin. Data is expressed as percent of
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duplicate.
Immunofluorescent staining
Cells were seeded on sterile glass coverslips as described
previously [12] and fixed in either cold methanol for 4 minutes
or 3% paraformaldehyde (PF) in 250 mM HEPES followed by a
permeabilization step in 6% PF with 0.25% Triton X-100 in
250 mM HEPES for 10 minutes each at room temperature (RT).
Cells were blocked with 2% chicken serum in PBS, incubated with
primary antibodies (Phosphoserine, Pan-cytokeratin, Pan-cytoker-
atin FITC conjugate, FAK phospho-tyrosine 861 (Sigma, St.
Louis, MO), Phospho-tyrosine (Zymed/Invitrogen, Carlsbad, CA),
or listed above) for 20–60 minutes at RT, followed by three washes
with PBS. Samples were incubated with appropriate secondary
antibodies conjugated to Alexa Fluor
488, Alexa Fluor
594 (Molec-
ular Probes, Eugene, OR) or TRITC (Sigma, St. Louis, MO) for
20 minutes at RT, followed by three washes with PBS. To stain
actin, coverslips were incubated with Alexa Flouor
488 conjugated
phalloidin (Molecular Probes, Eugene, OR) for 20 minutes.
Coverslips were mounted onto glass slides using Prolong Gold
Antifade mounting medium with DAPI (Invitrogen, Carlsbad,
CA).
Immunofluorescent micrographs were captured using a 60X
objective on a Nikon 80i epifluorescence microscope equipped
with UV, FITC and TRITC filters, and DS-Fi1 color and DS-U2
monochromatic cameras using NIS Elements BR 3.0 software
(Nikon Instruments, Inc.) and processed with Adobe PhotoshopH.
To compare protein expression levels and subcellular localization,
care was taken to ensure that micrographs were taken with the
same exposure time. For confocal microscopy, immunofluores-
cently labeled cells were imaged with a Swept Field Confocal
system (Prairie Technologies) on a Nikon Eclipse TE-2000U
inverted microscope equipped with a 606,1.4 NA Plan-Apochro-
matic phase–contrast objective lens and automated ProScan stage
(Prior Scientific). The confocal head was equipped with filters for
illumination at 488, 568, and 647 nm from a 400 mW argon laser
and a 150 mW krypton laser. Digital images were acquired with
an HQ2 CCD camera (Photometrics). Image acquisition, shutter,
Z-axis position, laser lines, and confocal system were all controlled
by NIS Elements AR software (Nikon). Z-series optical sections
through each cell were obtained at 0.6 mm steps. Images were
processed using Adobe PhotoshopH.
Quantitation of Filamentous Actin
Cells were seeded at 10,000 cells/well in a 24 well plate, and
parallel plates were used to determine the mean cell number per
well. Cells were fixed after 48 hours in 3% PF for 10 minutes
followed by permeabilization in 6% PF containing 0.5% Triton X-
100 for 10 minutes. Cells were quenched with 50 mM Glycine,
and washed with PBS followed by a 60 min blocking step with 2%
chicken serum for at least 60 minutes. F-actin was stained with
Alexa Fluor
488 conjugated phalloidin for 30 minutes, followed by
extensive washing to remove unbound phalloiden. Alexa Fluor
488
Phalloidin was subsequently solubilized with MeOH. Recovered
fluorescence (Ex488/Em525) was determined using a safire2
microplate reader (Tecan, Durham, NC) with Magellan v6.3 for
windows software (Tecan, Durham, NC). The amount of
filamentous actin is expressed as the average relative fluorescence
per cell 6 the standard deviation calculated with a standard
propagation of error equation s
z= square root [(s
x/average x)
2 +
(s
y/average y)
2] x average z, where in this experiment z is the
fluorescence/cell number, x fluorescence, y cell number, and s the
standard deviation [74].
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